ROLE OF THE PPARГ PROI2ALA POLYMORPHISM IN HYPERTENSION AND METABOLIC SYNDROME
https://doi.org/10.38109/2225-1685-2012-2-47-54
Abstract
Aim. То study prevalence of Pro12Ala polymorphism of the PPARγ gene in Uzbek hypertensive patients and healthy men and its association with blood pressure and cardiovascular remodeling process. Methods. We observed 169 hypertensive patients and 50 healthy men Uzbek nationality. Metabolic syndrome (MS) was defined according to IDF, 2005. It has been performed oral glucose tolerance test, echocardiography, reactive hyperemia test, definition of common carotid intima-media thickness, lipids, microalbuminuria (MAU). Genotyping of Pro12Ala polymorphism of the PPARγ gene was determined by PCR amplification with allele-specific primers. Results. Analysis of frequency distribution of Pro12Ala polymorphism of the PPARγ gene has shown significantly greater accumulation of Proallele both among hypertensive patients (89.9%) and healthy subjects (83%). There was no association between Pro12Ala polymorphism of the PPARγ gene and blood pressure, left ventricular mass lipid and glucose levels in hypertensive patients with MS. It has been revealed higher heart rate and MAU in hypertensive patients with MS-carriers of Proallele as compared with Ala-allele carriers. Genetic risk assessment of MS by multiplicative model of inheritance has shown that availability of Pro-allele has associated with high risk of MS (OR 1.73, 95%CI 0.84-3.37) but presence of Ala-allele has associated with low risk of MS (OR 0.58 95%CI 0.30-1.13). Conclusion. It has been found high frequency of Pro-allele and Pro/Pro genotype of Pro12Ala polymorphism of the PPARγ gene both among hypertensive patients with or without MS and healthy subjects of Uzbek nationality. Probability of MS development is higher in hypertensive patients with MS-carriers of Pro-allele of Pro12Ala polymorphism of the PPARγ gene as compared with Ala-allele carriers.
About the Authors
R. D. Kurbanov
Republic Specialized Centre of Cardiology
Russian Federation
Russian Federation
N. Z. Srojidinova
Republic Specialized Centre of Cardiology
Russian Federation
Russian Federation
References
1. Desvergne В., Michalik L., Wahli W. Transcriptional Regulation of Metabolism // Physiol. Rev. - 2006. -Vol. 86. - P. 465-514.
2. Desvergne В., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of Metabolism // Endoer. Rev. - 1999. - V. 20. - P. 649-688.
3. Kie-Wilk B., Dembinska-Kie A., Olszanecka A., et al. The selected pahtophysiological aspects of PPARs activation. // J. of Physiology and pharmacology -2005; 56 (2): p. 149-162.
4. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease // J. Clin. Invest. - 2006. - V. 116(3). - P. 581-585.
5. Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease// PPAR Research. - 2008. - Vol. 2008. - 11 Pages.
6. Yamamoto J., Kageyama S., Nemoto M. PPARg2 Prol2Ala Polymorphism and Insulin Resistance in Japanese Hypertensive Patients. // Hypertens Res 2002; 25: 25-29
7. Gonzalez Sanchez J. L., Serrano Rios М., Fernandez Perez C. et al. Effect of the Prol2Ala polymorphism of the peroxisome proliferator-activated receptor g-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. // European Journal of Endocrinology (2002) 147 495-501.
8. Frederiksen L., Brodbek K., Fenger M. et al. Studies of the Prol2Ala Polymorphism of the PPAR-Gene in the Danish MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. // J. Clin Endocrinol Metab 87: 3989-3992, 2002.
9. Dongxia L., Qi H., Lisong L., Jincheng G. Association of Peroxisome Proliferator-Activated Receptor Gene Prol2Ala and C161T Polymorphisms With Metabolic Syndrome. // Cire J. 2008; 72: 551 -557.
10. Мкртумян А. М., Бирюкова E. В., Маркина Н.В. Молекулярно-генетические особенности, характер метаболизма глюкозы и функция эндотелия у больных метаболическим синдромом русской популяции. // Сахарный диабет 2008; 4: 26-30.
11. Swarbrick M.M., Chapman C.M.L., McQuillan B.M.A. Prol2Ala polymorphism in the human peroxisome proliferator-activated receptor-g2 is associated with combined hyperlipidaemia in obesity. // European Journal of Endocrinology (2001) 144277-282.
12. Vaccaro O. et al. Prol2Ala polymorphism of the PPAR gamma 2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients // Diabetes Care. - 2007. - Vol. 30, № 5. p. 1156-1161.
13. Ghoussairii M., Meyre D., Lobbens S. et al. Implication of the Prol2Ala polimorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. // BMC MrdicalGenetics 2005: 6: 11: 1471-2350.
14. Cole S. A. et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-G2 (PPARG2) is associated with measures of obesity in Mexican Americans // Int. J. Obes. - 2000. - № 24. - P. 522-524.
15. Meirhaeghe A., Cottel D., Amouyel P., Dallongeville J. Association Between Peroxisome Proliferator-Activated Receptor Haplotypes and the Metabolic Syndrome in French Men and Women. // Diabetes 2005; 54: 3043-3048.
16. Hansen S.K., Nielsen E.M., Ek J., Andersen G. et al. Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes. J. Clin Endocrinol Metab. 2005; 90(6): 3629-3637.
17. Кобалава Ж.Д., Носиков B.B., Толкачева В.В. и др. Клинико-генетические детерминанты нарушений углеводного обмена у больных с артериальной гипертонией и избыточной массой тела. // Кардиология 2005; 4: 37-43.
Review
For citations:
Kurbanov R.D., Srojidinova N.Z. ROLE OF THE PPARГ PROI2ALA POLYMORPHISM IN HYPERTENSION AND METABOLIC SYNDROME. Eurasian heart journal. 2012;(2):47-54. (In Russ.) https://doi.org/10.38109/2225-1685-2012-2-47-54
Views:
362
Email this article 
